Emergent Technologies for Single-Cell Research
Infinitesimal LLC is a nanotechnology company and Northwestern University spin-off based in Skokie, Illinois, that develops systems for efficient and precise delivery of molecules into cells. The company holds an exclusive global license from Northwestern University for the patented nanofountain probe electroporation (NFP-E) technology, which enables single-cell selectivity, high transfection efficiency (up to 95%), and high cell viability (up to 92%). Infinitesimal's CellFab platform is an integrated system for high-throughput and automated single-cell transfection of induced pluripotent stem cells and other adherent cells, enabling multiplexed gene editing, isogenic cell line generation, and pharmacological studies. The company received NIH SBIR funding from the National Institutes of Health.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.
